RxDoctor Payments Data

Jonathan Berry, MD

Family Medicine · Little Rock, ARNPI 1346731932

Payments from drug & device makers

$8,847in general payments, 2019–2025

Across 592 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$977
  • AstraZeneca$889
  • Pfizer$722
  • GSK$707
  • Amgen$469
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$8,827100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,847 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$130,178
Medicare patients
462
Services billed
2,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$109,396
MounjaroTirzepatide55$60,006
JardianceEmpagliflozin39$39,680
EliquisApixaban36$39,097
FarxigaDapagliflozin Propanediol52$38,194
Soliqua 100-33Insulin Glargine/Lixisenatide20$25,792
Xultophy 100-3.6Insulin Degludec/Liraglutide26$25,416
TrulicityDulaglutide19$18,828
JanuviaSitagliptin Phosphate23$18,602
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$17,977
LinzessLinaclotide13$17,768
EntrestoSacubitril/Valsartan12$13,363
Tresiba Flextouch U-100Insulin Degludec17$10,407
SymbicortBudesonide/Formoterol Fumarate27$7,273
Breo ElliptaFluticasone/Vilanterol15$6,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$287$134,811124 claims
Lilly USA, LLCMounjaro, Trulicity$977$78,83374 claims
AstraZenecaFarxiga, Symbicort$889$45,46779 claims
Boehringer IngelheimJardiance$127$39,68039 claims
PfizerEliquis$722$39,09736 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$46$25,79220 claims
GSKTrelegy Ellipta, Breo Ellipta$707$24,56039 claims
AbbVieLinzess, Synthroid$1,829$19,35545 claims
MerckJanuvia$88$18,60223 claims
NovartisEntresto$122$13,36312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →